The Unreasonable Redundancy of Nature's Protein Folds
This article explores the application of deep learning models like AlphaFold3 to biomolecular design and protein folding. It argues that scaling compute and data is the primary driver for breakthroughs in drug discovery and antibody development.
Why it matters
Advancements in generative AI for biology could revolutionize pharmaceutical development and enable the creation of treatments for previously untreatable diseases.
Over the last few years, deep neural networks have made generative language modeling dramatically more powerful, giving us large language models. A similar leap happened for continuous modalities like images and videos. Recently, similar techniques have been applied to the generative modeling of biomolecules with great success. Models such as DeepMind's AlphaFold3 made it much easier to predict biomolecular interactions, including drug-protein and antibody-protein complexes, and soon after people figured out how to re-purpose these capabilities to design drug-like molecules. Chai-2 , Latent-X2 , and Nabla all report developable antibody or biologics designs. In the near future, we might see most antibodies entering the clinic designed in large part with deep-learning-based generative models, potentially with superior pharmaceutical properties and targeting receptors that have resisted wet-lab based approaches.
The article provides a technical overview of scientific progress without political or ideological framing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in